Annexin Pharmaceuticals AB (publ) (ANNX.ST)

SEK 0.29

(0.35%)

Long Term Debt Summary of Annexin Pharmaceuticals AB (publ)

  • Annexin Pharmaceuticals AB (publ)'s latest annual long term debt in 2023 was - SEK , down 0.0% from previous year.
  • Annexin Pharmaceuticals AB (publ)'s latest quarterly long term debt in 2024 Q3 was - SEK , down 0.0% from previous quarter.
  • Annexin Pharmaceuticals AB (publ) reported annual long term debt of - SEK in 2022, down 0.0% from previous year.
  • Annexin Pharmaceuticals AB (publ) reported annual long term debt of - SEK in 2021, down 0.0% from previous year.
  • Annexin Pharmaceuticals AB (publ) reported quarterly long term debt of - SEK for 2024 Q2, down 0.0% from previous quarter.
  • Annexin Pharmaceuticals AB (publ) reported quarterly long term debt of - SEK for 2024 Q3, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Annexin Pharmaceuticals AB (publ) (2023 - 2014)

Historical Annual Long Term Debt of Annexin Pharmaceuticals AB (publ) (2023 - 2014)

Year Long Term Debt Long Term Debt Growth
2023 - SEK 0.0%
2022 - SEK 0.0%
2021 - SEK 0.0%
2020 - SEK 0.0%
2019 - SEK -100.0%
2018 229 Thousand SEK -52.19%
2017 479 Thousand SEK -34.29%
2016 729 Thousand SEK -27.1%
2015 1 Million SEK 42.86%
2014 700 Thousand SEK 0.0%

Peer Long Term Debt Comparison of Annexin Pharmaceuticals AB (publ)

Name Long Term Debt Long Term Debt Difference
Active Biotech AB (publ) 3 Million SEK 100.0%
Biovica International AB (publ) 4.29 Million SEK 100.0%
Cantargia AB (publ) - SEK NaN%
CombiGene AB (publ) - SEK NaN%
Cyxone AB (publ) 74 Thousand SEK 100.0%
Diagonal Bio AB (publ) - SEK NaN%
Elicera Therapeutics AB (publ) - SEK NaN%
ExpreS2ion Biotech Holding AB (publ) 1.43 Million SEK 100.0%
Fluicell AB (publ) - SEK NaN%
Infant Bacterial Therapeutics AB (publ) - SEK NaN%
Mendus AB (publ) 850 Thousand SEK 100.0%
Isofol Medical AB (publ) - SEK NaN%
I-Tech AB - SEK NaN%
Intervacc AB (publ) 142 Thousand SEK 100.0%
Lipigon Pharmaceuticals AB (publ) - SEK NaN%
Magle Chemoswed Holding AB (publ) 32.58 Million SEK 100.0%
Modus Therapeutics Holding AB (publ) - SEK NaN%
OncoZenge AB (publ) - SEK NaN%
Sprint Bioscience AB (publ) - SEK NaN%
Xbrane Biopharma AB (publ) 112.89 Million SEK 100.0%
Lipum AB (publ) 1.76 Million SEK 100.0%
Alligator Bioscience AB (publ) 7.51 Million SEK 100.0%
Ziccum AB (publ) 286 Thousand SEK 100.0%
BioArctic AB (publ) 2.15 Million SEK 100.0%
Genovis AB (publ.) 74.8 Million SEK 100.0%
Camurus AB (publ) 13.61 Million SEK 100.0%
IRLAB Therapeutics AB (publ) 24.51 Million SEK 100.0%
Bio-Works Technologies AB (publ) - SEK NaN%
Aptahem AB (publ) - SEK NaN%
Vicore Pharma Holding AB (publ) - SEK NaN%
Xspray Pharma AB (publ) 31.94 Million SEK 100.0%
Kancera AB (publ) - SEK NaN%
Saniona AB (publ) 65.23 Million SEK 100.0%
Spago Nanomedical AB (publ) - SEK NaN%
AcouSort AB (publ) - SEK NaN%
Xintela AB (publ) - SEK NaN%
Abliva AB (publ) 424 Thousand SEK 100.0%
Karolinska Development AB (publ) - SEK NaN%
Amniotics AB (publ) - SEK NaN%
2cureX AB (publ) - SEK NaN%
Asarina Pharma AB (publ) 1 Million SEK 100.0%
Calliditas Therapeutics AB (publ) 939.5 Million SEK 100.0%
Hansa Biopharma AB (publ) 844.9 Million SEK 100.0%
Biosergen AB - SEK NaN%
QuiaPEG Pharmaceuticals Holding AB (publ) - SEK NaN%
Corline Biomedical AB - SEK NaN%
NextCell Pharma AB - SEK NaN%
Nanologica AB (publ) 136 Thousand SEK 100.0%
LIDDS AB (publ) - SEK NaN%
Egetis Therapeutics AB (publ) 103.4 Million SEK 100.0%
BioInvent International AB (publ) 14.53 Million SEK 100.0%
SynAct Pharma AB 58 Thousand SEK 100.0%
Stayble Therapeutics AB (publ) 850 Thousand SEK 100.0%
Alzinova AB (publ) 800 Thousand SEK 100.0%
Ascelia Pharma AB (publ) 176 Thousand SEK 100.0%
Oncopeptides AB (publ) 106.48 Million SEK 100.0%
Pila Pharma AB (publ) - SEK NaN%
Guard Therapeutics International AB (publ) - SEK NaN%
Scandinavian ChemoTech AB (publ) - SEK NaN%
Simris Alg AB (publ) 90.74 Million SEK 100.0%
Diamyd Medical AB (publ) 30.67 Million SEK 100.0%